- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03694756
TMEM-MRI: A Pilot Feasibility Study of MRI for Imaging of TMEM in Patients With Operable Breast Cancer (TMEM-MRI)
TMEM-MRI: A Pilot Feasibility Study of Magnetic Resonance Imaging for Imaging of TMEM (Tumor Microenvironment of Metastasis) in Patients With Operable Breast Cancer
Study Overview
Detailed Description
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Jesus Anampa, MD,MS
- Phone Number: 7184058505
- Email: janampa@montefiore.org
Study Locations
-
-
New York
-
Bronx, New York, United States, 10461
- Recruiting
- Montefiore Medical Center
-
Principal Investigator:
- Jesus Anampa, MD
-
Contact:
- Jesus D Anampa, MD,MS
- Phone Number: 718-405-8505
- Email: janampa@montefiore.org
-
Sub-Investigator:
- Joseph Sparano, MD
-
Contact:
- Karen Fehn, RN
- Phone Number: 7184058505
- Email: kfehn@montefiore.org
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria
For pre-pilot phase (MRI sequence development):
o Patients with a breast mass, with biopsy-proven histology of invasive breast carcinoma (any histologic type and ER,PR,HER2 status)
For pilot phase cohort A:
o Patients with a breast mass considered highly suspicious for invasive carcinoma by the radiologist (BIRADS 5).
For pilot phase cohort B:
- Patients with a breast mass found to be invasive ductal carcinoma on core biopsy.
- The tumor should be considered operable by the breast surgeon.
- No preoperative therapy for the current breast cancer is planned (endocrine therapy, chemotherapy, or radiation).
- Tumor size/breast mass should be > 1 cm in largest diameter (radiologically).
- Multifocal disease is allowed, as long as patients meet all eligibility criteria.
- Age ≥ 18 years.
- ECOG performance status 0-1.
- Willingness to undergo a "research breast MRI".
Patient must be able to undergo MRI with gadolinium enhancement.
- No history of untreatable claustrophobia.
- No presence of non MRI compatible metallic objects or metallic objects that, in the opinion of a radiologist, would make MRI a contraindication.
- No history of sickle cell disease.
- No contraindication to intravenous contrast administration.
- No known allergy-like reaction to gadolinium
- No known or suspected renal impairment. GFR should be greater than 30 mL/min/1.73 m2.
- Weight less than or equal to the MRI table limit.
- Ability to understand and willingness to sign a written informed consent.
Exclusion Criteria
- Patients may not have had breast cancer or radiation therapy to the ipsilateral breast in the past.
- No breast prosthetic implants (silicone or saline) are allowed.
- Use of any investigational agent within 30 days of starting study.
- Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study.
- Patients must be non-pregnant and non-lactating. Patients must have a negative pregnancy test (urine or serum) within 7 days of registration date.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Pre-biopsy patients
Patients identified by a radiologist at the time of diagnostic evaluation.
Once consent is obtained, the TMEM-MRI will be scheduled.
After TMEM-MRI, the patient will undergo core biopsy as per usual radiology procedure, with additional FNA at the time of core biopsy (preceding the core biopsy).
MenaINV and MenaCalc will be calculated from the FNA material.
After the breast biopsy confirms the suspected diagnosis of invasive breast carcinoma, the patient will be referred to breast surgery and a treatment plan devised, as per NCCN/ASCO guidelines.
TMEM density, MenaCalc and MenaINV will be also calculated from the specimen obtained at the time of definitive surgery.
Uth qTPERM will be correlated with TMEM density, MenaCalc and MenaINV.
|
TMEM MRI INFORMATION: Unilateral breast MRI will be obtained on a 3.0T whole body MRI scanner with a dedicated breast radiofrequency coil.
The patient will be scanned in the prone position with an in-dwelling IV catheter for a single dose contrast agent injection.
FNA: The patients who are recruited prior to biopsy (Cohort A) will have had TMEM-MRI performed prior to biopsy.
They will then present to radiology for ultrasound-guided core biopsy of the breast mass.
FNA will be performed during this procedure.
The FNA will be performed after local anesthetic is administered but prior to insertion of the core biopsy needle.
FNA will be performed by the radiologist under direct sonographic visualization of the mass.
Five passes will be obtained with a 25 gauge needle.
The FNA material will be expelled into 1.5 ml Eppendorf tube containing phosphate buffered saline with EDTA.
|
Other: Post-biopsy patients
Patients after breast biopsy.
Once consent is obtained, patients will undergo TMEM-MRI.
The patients will undergo definitive breast surgery and will receive adjuvant treatments as per NCCN/ASCO guidelines.
TMEM density, MenaCalc and MenaINV will be evaluated in final surgical specimen.
Uth qTPERM will be correlated with TMEM density, MenaCalc and MenaINV.
|
TMEM MRI INFORMATION: Unilateral breast MRI will be obtained on a 3.0T whole body MRI scanner with a dedicated breast radiofrequency coil.
The patient will be scanned in the prone position with an in-dwelling IV catheter for a single dose contrast agent injection.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Tumor permeability assessed by TMEM-MRI
Time Frame: It will take you about 24 months to complete this research study outcome.
|
Tumor permeability will be assessed by TMEM-MRI, and is defined as a number of Uth units (the number of tumor voxels with permeability density above threshold divided by the number of all tumor voxels) that will be obtained from the permeability map and TMEM-MRI algorithm.
|
It will take you about 24 months to complete this research study outcome.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
TMEM density in breast cancer patients.
Time Frame: It will take you about 24 months to complete this research study outcome.
|
TMEM density is defined as the number of TMEM units visualized by triple immunohistochemistry in 10 high power fields (40X).
TMEM density will be measured with a fully automated and scalable clinical assay for identification and enumeration of TMEM utilizing digital pathology methods coupled with image analysis
|
It will take you about 24 months to complete this research study outcome.
|
MenaCalc
Time Frame: It will take you about 24 months to complete this research study outcome.
|
MenaCalc is calculated by subtracting the Z-score value of Mena11a from the Z-score value of pan-Mena, obtained by quantitative immunohistochemistry in formalin-fixed paraffin-embedded breast tumor specimens.
MenaCalc can also be measured by qRT-PCR in cancer cells obtained by FNA
|
It will take you about 24 months to complete this research study outcome.
|
MenaInv
Time Frame: It will take you about 24 months to complete this research study outcome.
|
MenaInv is calculated as pixel intensity obtained by quantitative immunofluorescence per area of formalin-fixed paraffin-embedded tumor tissue.
MenaINV can also be measured by qRT-PCR in cancer cells obtained by FNA
|
It will take you about 24 months to complete this research study outcome.
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Jesus Anampa, MD,MS, Montefiore Medical Center
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2018-9529
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); Rutgers Cancer Institute of New JerseyActive, not recruitingStage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of WashingtonTerminatedBreast Cancer | Breast Cancer Stage I | Breast Cancer Stage II | Breast Cancer Stage III | Breast Cancer Stage IIB | Breast Cancer Stage IIA | Breast Cancer Stage IIIA | Breast Cancer Stage IIIB | Breast Cancer Stage IIIcUnited States
-
CelgeneCompletedBreast Cancer | Metastatic Breast Cancer | Stage IV Breast Cancer | Triple-negative Breast Cancer | Recurrent Breast Cancer | Breast Tumor | Cancer of the Breast | Triple-negative Metastatic Breast Cancer | Estrogen Receptor- Negative Breast Cancer | HER2- Negative Breast Cancer | Progesterone Receptor- Negative...United States, United Kingdom, Italy, Germany, Spain, Canada, Portugal, Australia, Austria, Greece, Brazil, France
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedHER2-positive Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Estrogen Receptor-negative Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-negative Breast Cancer | Progesterone Receptor-positive Breast...United States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Male Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Susan G. Komen Breast Cancer FoundationCompletedStage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
Northwestern UniversityEisai Inc.UnknownMale Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative...United States
-
Ohio State University Comprehensive Cancer CenterCompletedStage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Stage III Breast CancerUnited States
Clinical Trials on TMEM-MRI
-
Assistance Publique Hopitaux De MarseilleActive, not recruitingMultiple SclerosisFrance
-
Cambridge University Hospitals NHS Foundation TrustRecruitingBreast CancerUnited Kingdom
-
Seoul National University Bundang HospitalBayerCompletedTraumaKorea, Republic of
-
Vanderbilt-Ingram Cancer CenterNational Cancer Institute (NCI)TerminatedAdult Anaplastic Astrocytoma | Adult Anaplastic Ependymoma | Adult Anaplastic Oligodendroglioma | Adult Giant Cell Glioblastoma | Adult Glioblastoma | Adult Gliosarcoma | Recurrent Adult Brain TumorUnited States
-
Vanderbilt-Ingram Cancer CenterNational Cancer Institute (NCI)TerminatedOsteosarcoma | Ewing Sarcoma | Paget's DiseaseUnited States
-
University of ZurichBalgrist University HospitalNot yet recruiting
-
Bragee ClinicsNot yet recruitingChronic Fatigue Syndrome
-
Brighton and Sussex University Hospitals NHS TrustCompletedLacrimal Duct Obstruction | Lacrimal StenosisUnited Kingdom
-
Rennes University HospitalBayerTerminatedMultiple Sclerosis (MS) | Inflammatory DiseaseFrance
-
Memorial Sloan Kettering Cancer CenterTerminated